Apollomics vs Xenon Pharmaceuticals
APLM and XENE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How APLM and XENE compare
Xenon Pharmaceuticals scores higher on the StockData Score (7 against 0 for Apollomics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | APLM | XENE |
|---|---|---|
| Size and price | ||
| Market cap | – | $3.9B |
| Share price | $17.68 | $40.48 |
| Change, 1 year | 7.0% | 2.0% |
| Change, 5 years | – | 39.6% |
| Beta (5Y) | 0.68 | 0.62 |
| Employees | 14 | 370 |
| StockData Score | ||
| Total score | 0 | 7 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 0 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | – | 3.4× |
| FCF yield | – | −9.1% |
| Growth | ||
| Revenue growth (TTM) | – | −100% |
| Revenue growth, 5Y average | – | −25.3% |
| Profitability | ||
| Return on equity | – | −50.3% |
| Return on invested capital | – | −251% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Current ratio | 0.96 | 21.19 (better) |
| Altman Z-score | – | 41.77 |
| Piotroski F-score | – | 3 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | – | 104% |
| Held by insiders | 76.0% | 0.17% |
| Insider net buying, 12 months | $8.3M (better) | −$20.3M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | – | 7.6% |
Go deeper
- APLM stock overview
- APLM income statement
- APLM valuation and score
- XENE stock overview
- XENE income statement
- XENE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.